Opinion|Videos|May 29, 2024
Diabetes, GLP-1, and Lipid Reduction
Michael Blaha, MD, highlights the potential of GLP-1 agonists in lowering LDL cholesterol, triglycerides, and body weight in patients with diabetes, presenting them as an additional option for reducing cardiovascular risk in this patient population.
Advertisement
Episodes in this series
Advertisement
Related to this article
FDA approved mavacamten for oHCM in children weighing 30 kg or more after SCOUT-HCM showed a 48.0-mm Hg Valsalva LVOT gradient reduction vs placebo.
Jesus Almendral, MD, and Kanika Mody, MD, join the HCPLive team to discuss increases in hypertensive heart disease, heart failure, and other conditions.
Preview the biggest anticipated FDA decisions of Q4 2026, including bepirovirsen for CHB, obinutuzumab for pMN, bezuclastinib for systemic mastocytosis, and more.
Get a head start on one of the biggest heart failure conferences of the year with our HFSA 2026 preview.
Real-world COMPETE SWITCH CV data at EASD 2026 linked semaglutide 2 mg escalation to 6% lower MACE risk vs switching to tirzepatide in T2D.
Higher levels of Lp(a) are also associated with deep vein thrombosis and pulmonary embolism according to this retrospective cohort study.
Donald Cutlip, MD, discusses the sirolimus balloon’s approval and its role in clinical practice for patients with ISR.
Advertisement
Advertisement
Trending on HCPLive
1
US Alcohol Use Falls, but Not for Adults Aged 50 to 64, With Brian Lee, MD
2
EASD 2026: EloraTZP Bests Tirzepatide on Weight Loss, A1C in Type 2 Diabetes
3
FDA Approves Mavacamten for Pediatric Patients With Obstructive HCM
4
Nail Detachment 4 Times More Common With GLP-1 Use
5